U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H21N3O4
Molecular Weight 439.4636
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LESTAURTINIB

SMILES

C[C@]12[C@](C[C@]([H])(n3c4ccccc4c5c6c(CN=C6O)c7c8ccccc8n1c7c53)O2)(CO)O

InChI

InChIKey=UIARLYUEJFELEN-LROUJFHJSA-N
InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1

HIDE SMILES / InChI

Molecular Formula C26H21N3O4
Molecular Weight 439.4636
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Lestaurtinib (CEP-701, KT-5555) is an orally bio-available polyaromatic indolocarbazole alkaloid derived from K-252a. Lestaurtinib is a multi-targeted tyrosine kinase inhibitor which has been shown to potently inhibit FLT3 at nanomolar concentrations in preclinical studies, leading to its rapid development as a potential targeted agent for treatment of AML. Phase I studies have shown lestaturtinib to be an active agent particularly when used in combination with cytotoxic drugs. Currently, Phase II and Phase III studies are underway aiming to establish the future of this agent as a treatment option for patients with FLT3-ITD AML.

Approval Year

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
2014 Dec 5
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
2014 Jun 24
Patents

Sample Use Guides

Induction chemotherapy with or without sequential treatment with oral Lestaurtinib (CEP-701) at 80 mg bid. For patients with duration of first CR of 1 to 6 months, the induction regimen will be MEC.
Route of Administration: Oral
Lestaurtinib (CEP-701) potently inhibits FLT3/ITD autophosphorylation with a half maximal inhibitory concentration (IC50) of approximately 2 nM. Inhibition of FLT3 to 15% of its baseline level of autophosphorylation (the level of inhibition required to induce a significant cytotoxic effect on FLT3-dependent cell lines) occurs at a concentration of roughly 5 uM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:28:41 UTC 2021
Edited
by admin
on Sat Jun 26 02:28:41 UTC 2021
Record UNII
DO989GC5D1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LESTAURTINIB
INN   MART.   USAN   WHO-DD  
USAN   INN  
Official Name English
LESTAURTINIB [MART.]
Common Name English
SP924
Code English
CEP-701
Code English
KT-555
Code English
A-154475.0
Code English
LESTAURTINIB [INN]
Common Name English
KT-5555
Code English
A-154475
Code English
SP-924
Code English
SPM-924
Code English
LESTAURTINIB [USAN]
Common Name English
LESTAURTINIB [WHO-DD]
Common Name English
KT5555
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 219406
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
EU-Orphan Drug EU/3/06/389
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
NCI_THESAURUS C1967
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
FDA ORPHAN DRUG 289109
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
Code System Code Type Description
INN
8297
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
EVMPD
SUB32265
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
DRUG BANK
DB06469
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
MESH
C119379
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
EPA CompTox
111358-88-4
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
CAS
111358-88-4
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
FDA UNII
DO989GC5D1
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
ChEMBL
CHEMBL603469
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
NCI_THESAURUS
C48402
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
PUBCHEM
126565
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
WIKIPEDIA
LESTAURTINIB
Created by admin on Sat Jun 26 02:28:41 UTC 2021 , Edited by admin on Sat Jun 26 02:28:41 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY